SciencePart 1 of 5 in The T Files S6 — Metabolism

Fat Tissue Converts Testosterone Into Estradiol. That's Not a Malfunction.

Adipose tissue expresses aromatase, the enzyme that turns testosterone into estradiol. It is normal physiology — and it is one of the mechanisms linking higher body fat to lower testosterone in men.

By
Keen Clinician Team
Published
August 11, 2026
Last reviewed
August 11, 2026
Read time
3 min
Sources
4 cited

Adipose tissue is hormonally active, and one of the things it does is convert testosterone into estradiol via the enzyme aromatase. This is ordinary physiology — men are supposed to have estradiol, and aromatisation is how they get most of it. It becomes clinically interesting only as a matter of degree.

The relationship between androgens and obesity has been reviewed as a subject in its own right,[1] and it is one of the better-documented associations in male endocrinology.

Why fat mass matters to a hormone panel

More adipose tissue means more aromatase-expressing tissue. That shifts the balance of the androgen-to-estrogen conversion, and it is one contributor — not the only one — to the observation that higher body fat is associated with lower testosterone in men.

Two things follow, and they point in opposite directions clinically.

It makes low testosterone in men with obesity partly explicable. The finding has a mechanism behind it, rather than being a mysterious deficiency.

It makes the causal direction hard to establish. If adiposity lowers testosterone and lower testosterone favours adiposity, the association tells you very little about which came first — see the bidirectional trap.

The binding problem sits alongside it

Aromatase is only half of why adiposity distorts a testosterone reading. The other half is protein binding: most circulating testosterone is bound and unavailable to tissue, and the conditions that alter sex hormone-binding globulin change how much is free.[2]

Obesity is one of those conditions. So a man with significant adiposity can have a total testosterone value that misrepresents his free testosterone in either direction — which is exactly the situation in which the Endocrine Society guideline recommends obtaining a free testosterone concentration rather than relying on the total.[3]

The mechanics are in free vs total testosterone and SHBG and the binding problem.

What this means for a real panel

Body composition is context for the number. A total testosterone reading in a man with significant adiposity is harder to interpret in isolation than the same number in a lean man.

Free testosterone and SHBG earn their place on the panel. Not as extras — as the measurements that make the total interpretable.[3]

The cause matters before the treatment does. The guideline recommends additional diagnostic evaluation to establish the cause of a confirmed deficiency.[3] Adiposity is a common and partly modifiable contributor.

Frequently asked questions

Does losing weight raise testosterone? The androgen–obesity relationship is well described,[1] and unresolved questions remain about direction and about what interventions achieve — reviewed directly in the literature on hypogonadism and male obesity.[4] See does TRT fix obesity.

Should I take something to block aromatase? Not on the basis of this mechanism. Estradiol has necessary functions in men, and suppressing it is a clinical decision with its own risks, not a routine optimisation.

Is my high body fat why my testosterone is low? It may be a contributor. Establishing the cause is part of the diagnostic pathway rather than something to assume.[3]

Next in this series

Aromatase changes how much testosterone survives. Binding proteins change how much of what survives is usable.

Continue with SHBG and the binding problem.

References

4 sources
  1. Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17(3):224–232. doi:10.1097/MED.0b013e3283398ee2 · PMID 20418719
  2. Goldman AL, Bhasin S, Wu FCW, et al. A Reappraisal of Testosterone's Binding in Circulation: Physiological and Clinical Implications. Endocr Rev. 2017;38(4):302–324. doi:10.1210/er.2017-00025 · PMID 28673039
  3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
  4. Grossmann M. Hypogonadism and male obesity: Focus on unresolved questions. Clin Endocrinol (Oxf). 2018;89(1):11–21. doi:10.1111/cen.13723 · PMID 29683196

Feel like yourself again.